JP2023542820A5 - - Google Patents

Info

Publication number
JP2023542820A5
JP2023542820A5 JP2023513579A JP2023513579A JP2023542820A5 JP 2023542820 A5 JP2023542820 A5 JP 2023542820A5 JP 2023513579 A JP2023513579 A JP 2023513579A JP 2023513579 A JP2023513579 A JP 2023513579A JP 2023542820 A5 JP2023542820 A5 JP 2023542820A5
Authority
JP
Japan
Prior art keywords
cell culture
asparagine
antibody
fed
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542820A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047870 external-priority patent/WO2022047108A1/en
Publication of JP2023542820A publication Critical patent/JP2023542820A/ja
Publication of JP2023542820A5 publication Critical patent/JP2023542820A5/ja
Pending legal-status Critical Current

Links

JP2023513579A 2020-08-31 2021-08-27 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略 Pending JP2023542820A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063072740P 2020-08-31 2020-08-31
US202063072745P 2020-08-31 2020-08-31
US63/072,745 2020-08-31
US63/072,740 2020-08-31
PCT/US2021/047870 WO2022047108A1 (en) 2020-08-31 2021-08-27 Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants

Publications (2)

Publication Number Publication Date
JP2023542820A JP2023542820A (ja) 2023-10-12
JP2023542820A5 true JP2023542820A5 (enExample) 2024-09-03

Family

ID=78073988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513579A Pending JP2023542820A (ja) 2020-08-31 2021-08-27 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略

Country Status (14)

Country Link
US (2) US12163122B2 (enExample)
EP (1) EP4204578A1 (enExample)
JP (1) JP2023542820A (enExample)
KR (1) KR20230058094A (enExample)
CN (1) CN116209772A (enExample)
AU (1) AU2021332355A1 (enExample)
BR (1) BR112023003273A2 (enExample)
CA (1) CA3192999A1 (enExample)
CL (1) CL2023000576A1 (enExample)
CO (1) CO2023003662A2 (enExample)
IL (1) IL300828A (enExample)
MX (1) MX2023002417A (enExample)
TW (1) TW202432837A (enExample)
WO (1) WO2022047108A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901794B (zh) 2019-11-15 2026-05-01 隆萨有限公司 用于生产接种物的过程和系统
CN114836367A (zh) * 2022-04-28 2022-08-02 上海东富龙生物试剂有限公司 用于hek293细胞培养及腺病毒、腺相关病毒复制扩增的化学成分限定培养基

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
DE3271210D1 (en) 1981-12-24 1986-06-19 Asahi Chemical Ind Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7429491B2 (en) 2003-05-15 2008-09-30 Wyeth Restricted glucose feed for animal cell culture
EP1664283A4 (en) 2003-09-18 2007-12-26 Raven Biotechnologies Inc CELL CULTURE MEDIA
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US9096879B2 (en) 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
KR101662412B1 (ko) * 2011-07-01 2016-10-04 암젠 인크 포유동물 세포 배양
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
US10526631B1 (en) * 2016-03-15 2020-01-07 Ares Trading S.A. Method of reducing serine for asparagine misincorporation

Similar Documents

Publication Publication Date Title
TWI913830B (zh) 微晶片毛細管電泳分析及試劑
JP6971221B2 (ja) 組換えタンパク質のガラクトース含有量を増加させる方法
US12043845B2 (en) Methods of cell culture
JP7349998B2 (ja) サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
CN111630388B (zh) 用于表征蛋白质二聚化的系统和方法
CN107849139A (zh) 与人crth2特异性结合的抗体
JP2023548767A (ja) 抗体製造方法における相対不対グリカン
JP7321159B2 (ja) 薬剤生成物不純物を特性決定するためのシステム及び方法
US20250163182A1 (en) Enpp3 and cd3 binding agents and methods of use thereof
CN116209772A (zh) 用于提高细胞培养性能和减少天冬酰胺序列变体的天冬酰胺补料策略
JP7764361B2 (ja) Ｃｄ３に結合するバイスペシフィック抗体
US20210382067A1 (en) High-throughput and mass-spectrometry-based method for quantitating antibodies
US20260139059A1 (en) Cd161 binding proteins and related methods
CA3233279A1 (en) Fc-gamma receptor ii binding and glycan content
EA052717B1 (ru) Водный электрофоретический буфер для образца белкового лекарственного средства (варианты), способ выявления загрязнений или примесей в образце белкового лекарственного средства
EA041830B1 (ru) БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО, СВЯЗЫВАЮЩЕЕ ГЛИПИКАН 3 И CD3ε (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ЕГО, И СПОСОБ ПОЛУЧЕНИЯ ЭТОГО АНТИТЕЛА